WHO Approves First Malaria Drug for Newborns, "Artemether-lumefantrine" - Expected Current Affairs 2026

The World Health Organization (WHO) has approved the first malaria treatment specifically designed for newborns and young infants, marking a historic milestone in global health. Best Book for Current Affairs & General Knowledge Preparation

The drug, artemether-lumefantrine (commercially known as Coartem Baby), is the first formulation tailored for infants weighing 2–5 kg, addressing a long-standing treatment gap.

Earlier, infants were treated using medicines meant for older children, increasing risks of incorrect dosing, toxicity, and side effects. The new formulation ensures safer and more effective treatment outcomes.

WHO’s “prequalification” means the drug meets international standards of quality, safety, and efficacy, enabling procurement by UN agencies and global health programmes.

The drug was developed by Novartis in collaboration with Medicines for Malaria Venture (MMV), and will be distributed largely on a not-for-profit basis in malaria-endemic regions.

Malaria remains a major global challenge, with children under five being the most vulnerable, particularly in Africa. This innovation is expected to significantly reduce infant mortality rates.

The approval complements other interventions like malaria vaccines (RTS,S and R21), strengthening the global fight against this mosquito-borne disease.

This breakthrough reflects growing momentum in malaria control through targeted therapies, improved diagnostics, and integrated public health strategies.

Expected Current Affairs Questions for UPSC CDS NDA and AFCAT Written Exam

Q1. The first malaria drug approved specifically for newborns by WHO in 2026 is:

A. Artesunate

B. Artemether-lumefantrine

C. Chloroquine

D. Primaquine

Answer: B

Explanation: WHO prequalified artemether-lumefantrine (Coartem Baby), the first formulation designed specifically for newborns and infants.

Q2. Coartem Baby is primarily targeted at:

A. Adults with severe malaria

B. Pregnant women

C. Newborns and infants weighing 2–5 kg